Skip to main content

Table 2 (abstract A66). Characteristics of total population and patients divided into subgroups. Results reported as frequency (%) or mean (standard deviation)

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

Variable

All Patients (n = 2751)

Patients w Inactive Disease (n = 1249)

Patients w Active Disease (n = 1428)

SOCIODEMOGRAPHIC

 Age (years)

12.4 (4.7)

11.8 (4.8)

12.9 (4.6)

 Female

1675/2356 (71%)

723/1024 (71%)

929/1304 (71%)

 Race (White)

1885/2207 (85%)

824/970 (85%)

1045/1216 (86%)

 Insurance Status (Private)

1536/1769 (87%)

713/812 (88%)

814/946 (86%)

CLINICAL CHARACTERISTICS

 Disease Duration (months)

68.1 (49.1)

69.0 (48.4)

67.2 (49.4)

 ILAR Subtype

  Polyarticular, RF (-)

790 (29%)

350 (28%)

420 (29%)

  Oligoarticular, persistent

768 (28%)

417 (33%)

330 (23%)

  Enthesitis related arthritis

332 (12%)

115 (9%)

207 (14%)

  Oligoarticular, extended

286 (10%)

138 (11%)

136 (10%)

  Psoriatic arthritis

184 (7%)

61 (5%)

121 (8%)

  Systemic arthritis

174 (6%)

87 (7%)

83 (6%)

  Polyarticular, RF (+)

157 (6%)

55 (4%)

100 (7%)

  Undifferentiated

54 (2%)

25 (2%)

27 (2%)

  ANA Positive

1339 (49%)

611 (49%)

691 (49%)

DISEASE ACTIVITY MEASURES

 Active Uveitis

133/2393 (6%)

0

129/1286 (10%)

 Systemic Features

21 (<1%)

0

21 (1%)

 Morning Stiffness > 15 min

1934/2389 (81%)

0

452/1303 (35%)

 Elevated ESR / CRP

204 (7%) / 139 (5%)

0

204 (14%) / 139 (10%)

 Active Joint Count

0.9 (2.0)

0

1.8 (2.5)

 MD Global Assessment

1.0 (1.4)

0.03 (0.1)

1.8 (1.5)

PATIENT-REPORTED MEASURES

 Patient Global Assessment (0-10)

1.7 (2.3)

0.74 (1.5)

2.6 (2.5)

 Pain Score (0-10)

2 (2.5)

0.8 (1.5)

2.9 (2.8)

 CHAQ

0.24 (0.44)

0.11 (0.26)

0.36 (0.52)

MEDICATIONS

 Non-biologic DMARDs

1059 (38%)

399 (32%)

640 (45%)

  Methotrexate

914 (86%)

350 (88%)

549 (86%)

  Leflunomide

68 (6%)

24 (6%)

43 (7%)

  Sulfasalazine

51 (5%)

16 (4%)

34 (5%)

  Hydroxychloroquine

43 (4%)

7 (2%)

34 (5%)

  Other

14 (1%)

5 (1%)

10 (2%)

  More than one

33 (3%)

3 (<1%)

30 (5%)

 Biologic DMARDs

1101 (40%)

434 (35%)

684 (48%)

  All Anti-TNF

863 (31%)

350 (28%)

498 (35%)

   Etanercept

420 (38%)

191 (44%)

223 (33%)

   Adalimumab

331 (30%)

125 (29%)

202 (30%)

   Infliximab

105 (10%)

32 (7%)

68 (10%)

   Certolizumab

9 (<1%)

5 (1%)

4 (<1%)

   Golimumab

8 (<1%)

3 (<1%)

5 (<1%)

  Tocilizumab

97 (9%)

32 (7%)

64 (9%)

  Abatacept

80 (7%)

20 (5%)

60 (9%)

  Anakinra

23 (2%)

13 (3%)

9 (1%)

  Canakinumab

21 (2%)

12 (3%)

8 (1%)

  Rituximab

6 (<1%)

1 (<1%)

4 (<1%)

  Tofacitinib

4 (<1%)

0

4 (<1%)

  Other

2 (<1%)

2 (<1%)

0

  More than one

5 (<1%)

2 (<1%)

3 (<1%)

 NSAIDs

 Daily

770 (28%)

204 (16%)

551 (29%)

  Intermittent

345 (13%)

150 (12%)

195 (14%)

 Glucocorticoids

  Intra-articular

201 (7%)

46 (4%)

147 (10%)

  Systemic

84 (3%)

17 (1%)

63 (4%)

  Ophthalmic

119 (4%)

19 (2%)

94 (7%)

  1. A chi-square or t-test was performed to compare characteristics of patients with inactive and active disease. Results with p < 0.05 are bolded